Studies eptinezumab given during a migraine attack
Checks whether eptinezumab infusion helps end an ongoing migraine attack in adults.
Plain-language title generated from the registry record
Registry title: The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study)
Key facts
- Where
- Roma, ItalySee the site
Where in Italy
- Campus BiomedicoRoma, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Florence
- Trial code
- NCT06628921
- Record updated
- 21 January 2026
- Original description
A perspective and multicentric study to evaluate the efficacy of eptinezumab administered during a migraine attack. During the intravenous infusion of eptinezumab, some patients experiencing an ongoing migraine attack report its resolution. This finding is known in the literature, having been described in the RELIEF study. This study was designed to also evaluate, in a real-world setting, the efficacy of eptinezumab in resolving the ongoing attack and the time frame within which the attack is resolved.Read full original descriptionShow less
The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study)
A perspective and multicentric study to evaluate the efficacy of eptinezumab administered during a migraine attack. During the intravenous infusion of eptinezumab, some patients experiencing an ongoing migraine attack report its resolution. This finding is known in the literature, having been described in the RELIEF study. This study was designed to also evaluate, in a real-world setting, the efficacy of eptinezumab in resolving the ongoing attack and the time frame within which the attack is resolved.
The study includes all patients who will begin treatment according to clinical practice, and are included in the TACHIS study (NCT06409845, Unique protocol ID RICe_5)
Inclusion: Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the third edition of the ICHD (ICHD-III); At least 8 days of migraine per month; Adequate compliance with study procedures; Availability of a migraine diary for at least one month prior to enrollment; Ongoing attack before administration; Included in the TACHIS study (NCT06409845).
Exclusion: Concomitant diagnosis of medical conditions and/or comorbidities that, in the investigator's opinion, could interfere with the study's assessments and outcomes; Changes in concomitant preventive therapy in the month prior to the initiation of eptinezumab; Subjects with contraindications to the use of eptinezumab; Pregnancy and breastfeeding.